PHILADELPHIA, PA, UNITED STATES - Oct 29, 2015 - ERT, the leading cloud platform solutions provider delivering clinical and scientific innovation through its patient-centric data collection and intelligence solutions, today announced that its scientific and regulatory experts will be featured presenters at the International Society for Pharmacoeconomics Research (ISPOR) Annual European Congress, November 7-11, 2015 in Milan, Italy.

Members of ERT’s electronic Clinical Outcome Assessment (eCOA) Consulting Team will host:

-          “Patient-Reported Outcomes:  Can their Use in Observational (“real world”) Research be Considered Interventional?”; Panel session moderated by ERT Senior Scientist Matthew Reaney, CPsychol, CSci, MSc

-          “Equivalence of Paper and Electronic Administration of Patient Reported Outcomes:  A Comparison in Psoriatic Arthritis”; Podium presentation delivered by ERT Senior Scientist Matthew Reaney

Additionally the following research posters will be presented:

• “Assessment of Content Equivalence and Usability between the Paper and Electronic Versions of the Psoriasis Symptom and Sign Diary (PSSD) Among Subjects with Plaque Psoriasis”
• “Patient Reported Outcomes in the Development of New Medications for Type 2 Diabetes:  A Review of Recently Approved Products”
• “The Conceptual Framework and Content Validity of the Polycystic Ovary Syndrome Patient Reported Outcome Scale”
• “A Comprehensive Disease Model of Polycystic Ovary Syndrome”
• “Where is Your Abdomen?  Patient-Reported Abdomen Locations and Implications for Patient-Reported Outcome Assessments”
• “Usability Testing of an Integrated Glucometer and Handheld Electronic Patient-Reported Outcome System”
• “Engaging Patients with e-Clinical Technology:  Incorporating Patient Preferences into Disease Management and Care”
• “Patient Use of eClinical Technology to Research, Track and Self-Manage Chronic Disease”
• “Preference for Using Phone Calls, Text Messaging, and eMail to Communicate with Physicians among Patients with Four Chronic Diseases”
• “Review of Adherence Measures for Use in Phase IV Studies and Recommendations for a New Standardized Generic Measure”
• “Patient-Centered Reasons for Primary Non-Adherence as Derived from the Peer-Reviewed Literature”

“We’re pleased to have been invited to share our perspectives and learnings from collecting electronic Patient Reported Outcomes (ePRO) data across these varied therapeutic areas,” said Dr. Susan M. Dallabrida, eCOA Vice President of Clinical Science and Consulting, ERT.  “Our goal in participating at the ISPOR European Congress is to provide an opportunity for international researchers to stay updated on the latest regulatory, scientific and industry trends as they incorporate electronic clinical outcome assessments (eCOA) in their clinical development programs.”

For additional information on ERT’s involvement in the ISPOR Euro Congress visit https://www.ert.com/ispor-eu/

About ERT

ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) - which includes patient-, clinician-, observer- and performance-reported outcomes - and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products.

ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., and in Germany, Japan, Switzerland and the U.K.